이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Nevro 관리

관리 기준 확인 1/4

Nevro's CEO는 Kevin Thornal, Apr2023 에 임명되었습니다 의 임기는 1.17 년입니다. 총 연간 보상은 $ 11.45M, 4.5% 로 구성됩니다. 4.5% 급여 및 95.5% 보너스(회사 주식 및 옵션 포함). 는 $ 184.80K 가치에 해당하는 회사 주식의 0.057% 직접 소유합니다. 184.80K. 경영진과 이사회의 평균 재임 기간은 각각 1.3 년과 4.9 년입니다.

주요 정보

Kevin Thornal

최고 경영자

US$11.5m

총 보상

CEO 급여 비율	4.5%
CEO 임기	1.2yrs
CEO 소유권	0.06%
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	4.9yrs

최근 관리 업데이트

Recent updates

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

May 01

CEO 보상 분석

Kevin Thornal 의 보수는 Nevro 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$83m
Dec 31 2023	US$11m	US$516k	-US$92m

보상 대 시장: Kevin 의 총 보상 ($USD 11.45M )은 US 시장( $USD 2.46M ).

보상과 수익: Kevin 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Kevin Thornal (50 yo)

1.2yrs

테뉴어

US$11,453,548

보상

Mr. Kevin R. Thornal serves as President & Chief Executive Officer at Nevro Corp. since April 24, 2023 and serves as its Director since May 2023. He joined Nevro Corp. on April 24, 2023. He serves as Acti...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kevin Thornal	President	1.2yrs	US$11.45m	0.057% $ 167.0k
Roderick MacLeod	Senior VP & CFO	4yrs	US$2.58m	0.061% $ 179.5k
Kashif Rashid	Senior VP of Corporate Development & Chief Legal Officer	6.5yrs	US$2.55m	0.13% $ 365.7k
Greg Siller	Senior VP & Chief Commercial Officer	less than a year	US$3.56m	0.40% $ 1.2m
Christofer Christoforou	Senior VP & COO	less than a year	US$2.87m	0.074% $ 217.5k
Angeline McCabe	Vice President of Investor Relations & Corporate Communications	less than a year	데이터 없음	데이터 없음
Shana Ross	Senior VP & Chief Human Resources Officer	1.4yrs	데이터 없음	데이터 없음
David Caraway	Senior VP & Chief Medical Officer	10.2yrs	데이터 없음	데이터 없음
Peter Socarras	VP, General Counsel & Corporate Secretary	no data	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

50.5yo

평균 연령

경험이 풍부한 관리: NVRO 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kevin Thornal	President	1.1yrs	US$11.45m	0.057% $ 167.0k
Susan Siegel	Independent Director	3.5yrs	US$242.99k	0.035% $ 101.8k
Shawn McCormick	Independent Director	9.8yrs	US$246.99k	0.073% $ 213.9k
Elizabeth Weatherman	Independent Director	5.3yrs	US$259.24k	0.15% $ 444.0k
D. Grossman	Non-Executive Chairman of the Board	5.3yrs	US$1.48m	0.52% $ 1.5m
Michael DeMane	Independent Lead Director	13.3yrs	US$284.99k	1.28% $ 3.7m
Kevin O'Boyle	Independent Director	5.3yrs	US$259.99k	0.066% $ 192.8k
Kirt Karros	Independent Director	less than a year	데이터 없음	데이터 없음
Karen Prange	Independent Director	4.5yrs	US$252.99k	0.040% $ 117.6k
Sridhar Kosaraju	Independent Director	2.7yrs	US$242.99k	0.048% $ 140.6k

4.9yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: NVRO 의 이사회는 경험(평균 재직 기간 4.9 년)으로 간주됩니다.

Nevro 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Nevro Corp., Annual General Meeting, May 23, 2024

Independent Director recently bought US$172k worth of stock

Nevro Corp. Announces Executive Changes

Independent Lead Director exercised options to buy US$2.9m worth of stock.

Nevro Corp. Announces Executive Changes

General Counsel recently bought US$100k worth of stock

Recent updates

Consensus EPS estimates upgraded to US$2.31 loss

Price target decreased by 12% to US$16.63

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Nevro Corp. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Shareholder dilution

Nevro Corp., Annual General Meeting, May 23, 2024

Price target decreased by 9.5% to US$19.40

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Full year 2023 earnings: EPS exceeds analyst expectations

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024

There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nevro Corp. Increases Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$26.37

New major risk - Revenue and earnings growth

Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system

Consensus EPS estimates fall by 16%

Nevro Corp. Revises Earnings Guidance for the Full-Year 2023

New minor risk - Shareholder dilution

Price target decreased by 23% to US$28.80

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Price target decreased by 8.5% to US$37.57

Independent Director recently bought US$172k worth of stock

Price target decreased by 8.5% to US$38.43

Nevro Corp. Announces Executive Changes

Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Lead Director exercised options to buy US$2.9m worth of stock.

Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings

Nevro falls to 52-week low; down ~49% over last year

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains

Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Consensus forecasts updated

Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023

Nevro: Opportunity Overshadowed By Weaknesses

Price target decreased to US$47.73

Consensus forecasts updated

Price target decreased to US$50.36

Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022

Boston Scientific drives rival Nevro lower after remarks on neuromodulation

Price target decreased to US$53.91

Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval

Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022

Nevro gets FDA approval for Costa Rica manufacturing operations

Nevro Corp. Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Nevro Corp. Announces Executive Changes

Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation

Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations

Nevro Corp. Revises Earnings Guidance for the Full Year 2022

Nevro and Boston Scientific Corporation Announce the Settlement of Their Ongoing Intellectual Property Litigations

Nevro Corp. to Report Q2, 2022 Results on Aug 03, 2022

Nevro Corp. Announces the Complete 12-Month Results from the SENZA-PDN Randomized Controlled Trial

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Nevro: FDA Approved Lower Back Pain Relief Without Opiates Or Surgery

Price target decreased to US$69.50